In the treatment of early-stage HER2-positive breast cancer: The ATEMPT trial focused on a comparative analysis of the safety of T-DM1 versus paclitaxel plus trastuzumab (TH) in patients with early stage HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.